Taking tirzepatide and hydroxychloroquine together: the clinical picture

What hydroxychloroquine actually does to blood sugar, and why it matters here

Hydroxychloroquine (HCQ) is an antimalarial medicine used long-term for autoimmune conditions including systemic lupus erythematosus and rheumatoid arthritis. A well-documented and sometimes overlooked property of HCQ is its glucose-lowering effect. Several observational studies and a body of mechanistic research have shown it can reduce fasting glucose, improve insulin sensitivity, and in some people with type 2 diabetes, lower HbA1c modestly. That is not why it is prescribed, but it is a real pharmacological fact that any prescriber adding a second glucose-influencing medicine needs to account for.

Tirzepatide, a dual GIP and GLP-1 receptor agonist made by Eli Lilly and marketed in the UK as Mounjaro, lowers blood glucose through a different mechanism: it stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon. Because tirzepatide's insulin-releasing effect is glucose-dependent, the theoretical risk of true hypoglycaemia (very low blood sugar) is lower than with insulin or sulfonylureas, but it is not zero, particularly when a second agent with glucose-lowering properties is already present. The NHS tirzepatide medicines page lists dizziness, shakiness and cold sweats among symptoms worth monitoring; these overlap with hypoglycaemia signs. Worth flagging at your consultation.

The clinical message is not that the combination is forbidden. It is that the prescriber needs the full picture to weigh the benefit for your weight and your underlying autoimmune condition against any added monitoring burden.

QT interval and cardiac considerations, the less-discussed angle

A lesser-known aspect of this interaction is the cardiac conduction question. Hydroxychloroquine carries a known, dose-dependent effect on the QT interval, the part of the heart's electrical cycle measured on an ECG. At standard doses for autoimmune disease, this effect is generally modest, but it is not absent. The Summary of Product Characteristics on the eMC for hydroxychloroquine lists QT prolongation as a risk, particularly in patients with pre-existing cardiac conditions or those taking other QT-affecting drugs.

Tirzepatide itself does not appear in QT-prolongation databases as a primary concern, and the SURMOUNT-1 trial (which enrolled 2,539 adults over 72 weeks) did not flag cardiac conduction as a safety signal. However, your prescriber will still want to know your cardiac history before starting any new medicine in this setting. If you have a history of arrhythmia, a prolonged QT interval on a previous ECG, or you are taking other medicines that affect cardiac conduction, that conversation with your clinician is not optional, it is the right clinical step. Knowing about other conditions that interact with tirzepatide may also be relevant if you carry more than one diagnosis.

People sometimes assume that because these medicines are prescribed for entirely different conditions they simply cannot interact. They can, through shared physiological pathways even without a direct pharmacokinetic clash.

How prescribers at a regulated UK pharmacy approach this combination

When someone taking hydroxychloroquine applies for tirzepatide through a GPhC-registered online pharmacy, the consultation is not a box-ticking exercise. A named, GPhC-registered Independent Prescriber reads your full answers, every current medicine, every diagnosis, every relevant history point. Hydroxychloroquine will appear on that list, and the prescriber will consider it alongside your BMI, your weight-related conditions, and whether tirzepatide's licensed eligibility criteria are met.

The private licensed eligibility for tirzepatide hydrochloride is adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as hypertension, dyslipidaemia, prediabetes or type 2 diabetes. Rheumatoid arthritis and lupus themselves can be complicated by excess weight, and weight loss may have meaningful benefits for joint load and inflammatory markers, your prescriber can weigh that clinical context. If you are curious about what the assessment involves, the tirzepatide overview page covers eligibility and the consultation process in full.

It is also worth knowing that if you are on HRT alongside all of this, there is specific guidance for tirzepatide users about transdermal versus oral preparations; the HRT and tirzepatide page sets that out clearly. For context on what transparent private treatment costs, the Mounjaro cost page explains what legitimate pricing typically includes.

Practical steps before you start tirzepatide

If you are on hydroxychloroquine and considering tirzepatide, a few practical things matter before any prescription is written. First, list every medicine you take, including the dose and how long you have been on it. This is not bureaucracy, it is the information the prescriber needs to make a safe decision. Second, if you have had any cardiac investigations (an ECG, a cardiology referral), note the date and any findings. Third, if you monitor your own blood glucose, know your recent numbers; it gives the prescriber a baseline.

The MHRA's Yellow Card scheme remains open for reporting any unexpected effects once treatment starts, and your prescriber should be the first call if anything changes after you begin tirzepatide. Dose changes and titration decisions rest with the clinician, not with the Patient Information Leaflet alone. Our clinical team's approach is described on the prescriber profile page. When you are ready to understand whether tirzepatide is appropriate for your specific situation, a free consultation with a prescriber is the right next step, check your eligibility at our treatment page.